{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:33:28Z","timestamp":1795088008140,"version":"4.10.2"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2008347"],"award-info":[{"award-number":["2008347"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2012351"],"award-info":[{"award-number":["2012351"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2012351"],"award-info":[{"award-number":["2012351"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1195437"],"award-info":[{"award-number":["1195437"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T-cell immunotherapy has shown great success in clinical cancer, bringing hope to apply CAR strategies to other clinical settings. Here we developed a CAR macrophage (CAR-M) that recognizes the major inflammatory molecule tumour necrosis factor (TNF) and activates an intracellular IL-4 signalling pathway, thereby programming engineered macrophages for an anti-inflammatory function. CAR-M therapy has exhibited efficacy in mouse models of both acute and chronic inflammatory diseases. In kidney ischaemia reperfusion injury (IRI), infused CAR-Ms switched to an anti-inflammatory phenotype in inflamed kidney and attenuated kidney IRI. The anti-inflammatory phenotype of infused CAR-Ms switched off during the recovery phase of kidney IRI, coinciding with the disappearance of TNF. In Adriamycin-induced nephropathy, a model of chronic inflammatory disease, infused CAR-Ms maintained an anti-inflammatory phenotype for several weeks in response to sustained high levels of TNF and improved kidney function and structure. CAR-Ms also effectively reduced tissue injury in another organ, the liver. Human anti-TNF CAR-Ms exhibit anti-inflammatory phenotype and function in response to TNF. The CAR-M design, using signal switching, holds promise for the treatment of a broad range of acute and chronic inflammatory diseases.<\/jats:p>","DOI":"10.1038\/s41551-025-01387-8","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T05:02:19Z","timestamp":1746594139000},"page":"1502-1516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Targeting inflammation with chimeric antigen receptor macrophages using a signal switch"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3546-0766","authenticated-orcid":false,"given":"Qi","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Gloss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9400-3696","authenticated-orcid":false,"given":"Vincent W. S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leighton","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha M.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen I.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1721-8922","authenticated-orcid":false,"given":"Di","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C. H.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"1387_CR1","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.immuni.2022.03.016","volume":"55","author":"C Nathan","year":"2022","unstructured":"Nathan, C. Nonresolving inflammation redux. Immunity 55, 592\u2013605 (2022).","journal-title":"Immunity"},{"key":"1387_CR2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature12034","volume":"496","author":"TA Wynn","year":"2013","unstructured":"Wynn, T. A., Chawla, A. & Pollard, J. W. Macrophage biology in development, homeostasis and disease. Nature 496, 445\u2013455 (2013).","journal-title":"Nature"},{"key":"1387_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41423-020-00541-3","volume":"18","author":"DM Mosser","year":"2021","unstructured":"Mosser, D. M., Hamidzadeh, K. & Goncalves, R. Macrophages and the maintenance of homeostasis. Cell Mol. Immunol. 18, 579\u2013587 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"1387_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/sj.ki.5002275","volume":"72","author":"Y Wang","year":"2007","unstructured":"Wang, Y. et al. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int. 72, 290\u2013299 (2007).","journal-title":"Kidney Int."},{"key":"1387_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1681\/ASN.2009060592","volume":"21","author":"Q Cao","year":"2010","unstructured":"Cao, Q. et al. IL-10\/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. J. Am. Soc. Nephrol. 21, 933\u2013942 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1387_CR6","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.2337\/db11-1635","volume":"61","author":"R Parsa","year":"2012","unstructured":"Parsa, R. et al. Adoptive transfer of immunomodulatory M2 macrophages prevents type 1 diabetes in NOD mice. Diabetes 61, 2881\u20132892 (2012).","journal-title":"Diabetes"},{"key":"1387_CR7","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1053\/j.gastro.2009.12.041","volume":"138","author":"MM Hunter","year":"2010","unstructured":"Hunter, M. M. et al. In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology 138, 1395\u20131405 (2010).","journal-title":"Gastroenterology"},{"key":"1387_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbi.2014.11.007","volume":"45","author":"SF Ma","year":"2015","unstructured":"Ma, S. F. et al. Adoptive transfer of M2 macrophages promotes locomotor recovery in adult rats after spinal cord injury. Brain Behav. Immun. 45, 157\u2013170 (2015).","journal-title":"Brain Behav. Immun."},{"key":"1387_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00395-019-0742-1","volume":"114","author":"MN Podaru","year":"2019","unstructured":"Podaru, M. N. et al. Reparative macrophage transplantation for myocardial repair: a refinement of bone marrow mononuclear cell-based therapy. Basic Res. Cardiol. 114, 34 (2019).","journal-title":"Basic Res. Cardiol."},{"key":"1387_CR10","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/ki.2013.341","volume":"85","author":"Q Cao","year":"2014","unstructured":"Cao, Q. et al. Failed renoprotection by alternatively activated bone marrow macrophages is due to a proliferation-dependent phenotype switch in vivo. Kidney Int. 85, 794\u2013806 (2014).","journal-title":"Kidney Int."},{"key":"1387_CR11","doi-asserted-by":"publisher","first-page":"e102994","DOI":"10.1371\/journal.pone.0102994","volume":"9","author":"N Jetten","year":"2014","unstructured":"Jetten, N. et al. Wound administration of M2-polarized macrophages does not improve murine cutaneous healing responses. PLoS ONE 9, e102994 (2014).","journal-title":"PLoS ONE"},{"key":"1387_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1054938","volume":"13","author":"C Liang","year":"2022","unstructured":"Liang, C. et al. Engineered M2a macrophages for the treatment of osteoarthritis. Front. Immunol. 13, 1054938 (2022).","journal-title":"Front. Immunol."},{"key":"1387_CR13","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/s12276-023-01068-z","volume":"55","author":"YR Na","year":"2023","unstructured":"Na, Y. R., Kim, S. W. & Seok, S. H. A new era of macrophage-based cell therapy. Exp. Mol. Med 55, 1945\u20131954 (2023).","journal-title":"Exp. Mol. Med"},{"key":"1387_CR14","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/s41591-019-0599-8","volume":"25","author":"F Moroni","year":"2019","unstructured":"Moroni, F. et al. Safety profile of autologous macrophage therapy for liver cirrhosis. Nat. Med. 25, 1560\u20131565 (2019).","journal-title":"Nat. Med."},{"key":"1387_CR15","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1387_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol. Cancer 22, 20 (2023).","journal-title":"Mol. Cancer"},{"key":"1387_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan, K. et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J. Exp. Clin. Cancer Res. 41, 119 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1387_CR18","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1387_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A. & June, C. H. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707\u2013715 (2023).","journal-title":"Nature"},{"key":"1387_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian, H. et al. Targeting cardiac fibrosis with engineered T cells. Nature 573, 430\u2013433 (2019).","journal-title":"Nature"},{"key":"1387_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.cell.2007.12.030","volume":"132","author":"SL LaPorte","year":"2008","unstructured":"LaPorte, S. L. et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4\/13 system. Cell 132, 259\u2013272 (2008).","journal-title":"Cell"},{"key":"1387_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nchembio.2565","volume":"14","author":"ZL Chang","year":"2018","unstructured":"Chang, Z. L. et al. Rewiring T-cell responses to soluble factors with chimeric antigen receptors. Nat. Chem. Biol. 14, 317\u2013324 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"1387_CR23","doi-asserted-by":"publisher","first-page":"107879","DOI":"10.1016\/j.pharmthera.2021.107879","volume":"227","author":"D Panigrahy","year":"2021","unstructured":"Panigrahy, D., Gilligan, M. M., Serhan, C. N. & Kashfi, K. Resolution of inflammation: an organizing principle in biology and medicine. Pharmacol. Ther. 227, 107879 (2021).","journal-title":"Pharmacol. Ther."},{"key":"1387_CR24","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/ki.2011.446","volume":"81","author":"M Jung","year":"2012","unstructured":"Jung, M. et al. Infusion of IL-10-expressing cells protects against renal ischemia through induction of lipocalin-2. Kidney Int. 81, 969\u2013982 (2012).","journal-title":"Kidney Int."},{"key":"1387_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102920","volume":"58","author":"J Wu","year":"2020","unstructured":"Wu, J. et al. Macrophage phenotypic switch orchestrates the inflammation and repair\/regeneration following acute pancreatitis injury. EBioMedicine 58, 102920 (2020).","journal-title":"EBioMedicine"},{"key":"1387_CR26","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/mt.2014.47","volume":"22","author":"AM Leen","year":"2014","unstructured":"Leen, A. M. et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther. 22, 1211\u20131220 (2014).","journal-title":"Mol. Ther."},{"key":"1387_CR27","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/2159-8290.CD-20-0896","volume":"11","author":"S Lange","year":"2021","unstructured":"Lange, S. et al. A chimeric GM-CSF\/IL18 receptor to sustain CAR T-cell function. Cancer Discov. 11, 1661\u20131671 (2021).","journal-title":"Cancer Discov."},{"key":"1387_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85\u201396 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1387_CR29","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett, G., Mackensen, A. & Mougiakakos, D. CAR T-cell therapy in autoimmune diseases. Lancet 402, 2034\u20132044 (2023).","journal-title":"Lancet"},{"key":"1387_CR30","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"1387_CR31","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.it.2023.04.005","volume":"44","author":"S Bittner","year":"2023","unstructured":"Bittner, S., Hehlgans, T. & Feuerer, M. Engineered Treg cells as putative therapeutics against inflammatory diseases and beyond. Trends Immunol. 44, 468\u2013483 (2023).","journal-title":"Trends Immunol."},{"key":"1387_CR32","doi-asserted-by":"publisher","first-page":"661875","DOI":"10.3389\/fimmu.2021.661875","volume":"12","author":"C Selck","year":"2021","unstructured":"Selck, C. & Dominguez-Villar, M. Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation. Front. Immunol. 12, 661875 (2021).","journal-title":"Front. Immunol."},{"key":"1387_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cbpa.2021.05.012","volume":"64","author":"O Madderson","year":"2021","unstructured":"Madderson, O., Teixeira, A. P. & Fussenegger, M. Emerging mammalian gene switches for controlling implantable cell therapies. Curr. Opin. Chem. Biol. 64, 98\u2013105 (2021).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"1387_CR34","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.20.01467","volume":"38","author":"KM Cappell","year":"2020","unstructured":"Cappell, K. M. et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 38, 3805\u20133815 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1387_CR35","doi-asserted-by":"publisher","first-page":"eabn3353","DOI":"10.1126\/scitranslmed.abn3353","volume":"14","author":"GM Chen","year":"2022","unstructured":"Chen, G. M., Melenhorst, J. J. & Tan, K. B cell targeting in CAR T cell therapy: side effect or driver of CAR T cell function? Sci. Transl. Med. 14, eabn3353 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1387_CR36","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/ASN.2013121336","volume":"26","author":"Q Cao","year":"2015","unstructured":"Cao, Q. et al. Renal F4\/80+ CD11c+ mononuclear phagocytes display phenotypic and functional characteristics of macrophages in health and in adriamycin nephropathy. J. Am. Soc. Nephrol. 26, 349\u2013363 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1387_CR37","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/hep.22011","volume":"47","author":"EB Alabraba","year":"2008","unstructured":"Alabraba, E. B. et al. Coculture of human liver macrophages and cholangiocytes leads to CD40-dependent apoptosis and cytokine secretion. Hepatology 47, 552\u2013562 (2008).","journal-title":"Hepatology"},{"key":"1387_CR38","doi-asserted-by":"publisher","first-page":"16513","DOI":"10.1073\/pnas.1821601116","volume":"116","author":"S Nepal","year":"2019","unstructured":"Nepal, S. et al. STAT6 induces expression of Gas6 in macrophages to clear apoptotic neutrophils and resolve inflammation. Proc. Natl Acad. Sci. USA 116, 16513\u201316518 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1387_CR39","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1681\/ASN.2017070774","volume":"29","author":"Q Cao","year":"2018","unstructured":"Cao, Q. et al. Potentiating tissue-resident type 2 innate lymphoid cells by IL-33 to prevent renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 29, 961\u2013976 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1387_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.kint.2019.07.019","volume":"97","author":"Q Cao","year":"2020","unstructured":"Cao, Q. et al. Regulatory innate lymphoid cells suppress innate immunity and reduce renal ischemia\/reperfusion injury. Kidney Int. 97, 130\u2013142 (2020).","journal-title":"Kidney Int."},{"key":"1387_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100837","volume":"5","author":"Q Cao","year":"2023","unstructured":"Cao, Q. et al. Type 2 innate lymphoid cells are protective against hepatic ischaemia\/reperfusion injury. JHEP Rep. 5, 100837 (2023).","journal-title":"JHEP Rep."},{"key":"1387_CR42","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1681\/ASN.2014050479","volume":"26","author":"Q Huang","year":"2015","unstructured":"Huang, Q. et al. IL-25 elicits innate lymphoid cells and multipotent progenitor type 2 cells that reduce renal ischemic\/reperfusion injury. J. Am. Soc. Nephrol. 26, 2199\u20132211 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1387_CR43","doi-asserted-by":"crossref","first-page":"F129","DOI":"10.1152\/ajpcell.1998.274.1.C129","volume":"274","author":"RB Doctor","year":"1998","unstructured":"Doctor, R. B., Chen, J., Peters, L. L., Lux, S. E. & Mandel, L. J. Distribution of epithelial ankyrin (Ank3) spliceoforms in renal proximal and distal tubules. Am. J. Physiol. 274, F129\u2013F138 (1998).","journal-title":"Am. J. Physiol."},{"key":"1387_CR44","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1006\/jsre.2001.6201","volume":"99","author":"KK Meldrum","year":"2001","unstructured":"Meldrum, K. K., Meldrum, D. R., Hile, K. L., Burnett, A. L. & Harken, A. H. A novel model of ischemia in renal tubular cells which closely parallels in vivo injury. J. Surg. Res. 99, 288\u2013293 (2001).","journal-title":"J. Surg. Res."},{"key":"1387_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1387_CR46","doi-asserted-by":"publisher","first-page":"F561","DOI":"10.1152\/ajprenal.00538.2017","volume":"314","author":"Q Cao","year":"2018","unstructured":"Cao, Q. et al. Therapeutic potential of regulatory macrophages generated from peritoneal dialysate in adriamycin nephropathy. Am. J. Physiol. Renal Physiol. 314, F561\u2013F571 (2018).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"1387_CR47","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2119\/molmed.2011.00308","volume":"18","author":"TH Kim","year":"2012","unstructured":"Kim, T. H., Yoon, S. J. & Lee, S. M. Genipin attenuates sepsis by inhibiting Toll-like receptor signaling. Mol. Med. 18, 455\u2013465 (2012).","journal-title":"Mol. Med."},{"key":"1387_CR48","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1172\/JCI200316867","volume":"111","author":"N Grabie","year":"2003","unstructured":"Grabie, N. et al. IL-12 is required for differentiation of pathogenic CD8+ T cell effectors that cause myocarditis. J. Clin. Invest. 111, 671\u2013680 (2003).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01387-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01387-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01387-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T22:02:01Z","timestamp":1758146521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01387-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["1387"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01387-8","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"27 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}